Skórski T, Kawalec M, Kawiak J
Medical Center of Postgraduate Education, Department of Cytophysiology, Warsaw, Poland.
Cancer Immunol Immunother. 1990;32(1):71-4. doi: 10.1007/BF01741728.
The effectiveness of adoptive immunotherapy in eliminating minimal residual disease in tumour-bearing mice after bone marrow transplantation was tested. This model mimics the human clinical condition when autologous bone marrow was purged ex vivo of leukaemia with mafosfamide or was not purged, and stored in liquid nitrogen before transplantation. Animals with minimal residual disease were prepared with marrow-ablative but leukaemia-noncurative doses of cyclophosphamide (CY) and total body irradiation followed by bone marrow transplantation. The next day after transplantation the recipients were injected with splenocytes immunized against the leukaemia cells (Imm-SPL) or monoclonal antibody (mAb). All the control mice died from leukaemia relapse, but 51% of purged bone marrow recipients, which received Imm-SPL, were cured. In similar conditions mAb did not exert a therapeutic effect. Imm-SPL were not able to eradicate minimal residual disease in the recipients of nonpurged bone marrow. Thus, in an animal model, we demonstrated that purging of bone marrow before grafting seems to be indispensable for successful adoptive immunotherapy of minimal residual disease (MRD) after autologous bone marrow transplantation.
对过继性免疫疗法在骨髓移植后清除荷瘤小鼠微小残留病方面的有效性进行了测试。该模型模拟了人类临床情况，即自体骨髓在体外使用马磷酰胺清除白血病细胞或未进行清除，然后在液氮中保存直至移植。用骨髓清除但白血病未治愈剂量的环磷酰胺（CY）和全身照射，随后进行骨髓移植，制备出有微小残留病的动物。移植后第二天，给受体注射针对白血病细胞免疫的脾细胞（免疫脾细胞）或单克隆抗体（mAb）。所有对照小鼠均死于白血病复发，但接受免疫脾细胞的经清除骨髓受体中有51%被治愈。在类似条件下，mAb未发挥治疗作用。免疫脾细胞无法清除未清除骨髓受体中的微小残留病。因此，在动物模型中，我们证明移植前对骨髓进行清除似乎是自体骨髓移植后成功进行微小残留病（MRD）过继性免疫治疗必不可少的条件。
